• Angiotensin II: Practical Protocol and QC Guide

  2026-08-14

  Angiotensin II (SKU A1042) provides a defined octapeptide stimulus for receptor-binding assays, vascular smooth muscle cell hypertrophy research, hypertension mechanism studies, and vascular remodeling workflows. It is intended for controlled scientific experiments only, not for diagnosis, treatment, or direct translation of animal dosing to clinical use.

• 5-hme-dCTP: Designing Better 5hmC Assays

  2026-08-14

  5-hme-dCTP is more than a modified nucleotide: it is a defined reagent for separating polymerase chemistry from endogenous 5hmC biology. This guide connects B8113 assay design with the latest rice drought-response evidence while emphasizing controls, interpretation, and storage.

• DOT1L Inhibition Potentiates Lenalidomide in Myeloma

  2026-08-13

  The 2025 Cancer Letters study identifies DOT1L as a preferential epigenetic dependency in multiple myeloma and shows that its inhibition activates type I interferon and STING-associated innate immune signaling. These findings provide a mechanistic rationale for combining DOT1L inhibition with lenalidomide, because the epigenetic intervention increased interferon-regulated gene expression while weakening IRF4–MYC signaling.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-13

  Oliveira et al. show that naturally occurring angiotensin fragments can alter SARS-CoV-2 spike-protein binding to host receptors, with particularly strong effects on AXL. The structure–activity analysis identifies peptide length, N-terminal deletion, and tyrosine modification as important variables, providing a mechanistic starting point for studying links between renin–angiotensin signaling and viral-entry biology.

• FCCP Workflows for Mitochondrial and HIF Research

  2026-08-12

  FCCP connects mitochondrial proton-gradient disruption with measurable changes in oxygen consumption, ATP production, and HIF-associated signaling. This guide separates acute bioenergetic assays from longer cancer-cell treatments and shows how the compound can complement emerging tumor-associated macrophage immunometabolism research.

• Beyond Viability: Measuring Cancer Drug Responses

  2026-08-12

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that anti-cancer drugs can combine proliferative arrest and cell killing in different proportions and on different timescales. This dual-metric framework offers a more precise way to design and interpret in vitro drug-response experiments, while clarifying what viability measurements can and cannot predict in translational models.

• Angiotensin III: Mechanism-First Research Guide

  2026-08-11

  Explore how Angiotensin III and its Arg-Val-Tyr-Ile-His-Pro-Phe sequence shape RAAS signaling, endocrine responses, and receptor-aware assay design. This guide connects established cardiovascular biology with a recent binding-assay innovation while clearly separating validated evidence from emerging hypotheses.

• TMRE and the New Logic of Mitochondrial Failure

  2026-08-11

  Mitochondrial membrane potential is more than a viability signal: it is a mechanistic waypoint connecting ion imbalance, energy failure, and cell fate. This article explains how the TMRE mitochondrial membrane potential assay kit can help translational researchers validate sodium-driven mitochondrial dysfunction while avoiding the interpretive limits of a single fluorescent endpoint.

• Lenalidomide in Myeloma Research Workflows

  2026-08-10

  Lenalidomide (CC-5013) supports integrated myeloma experiments that connect direct tumor-cell effects with immune restoration, interferon signaling, and angiogenesis control. This guide translates recent DOT1L findings into practical combination assays, dosing workflows, and troubleshooting decisions.

• Reversine and the Logic of Aurora Kinase Control

  2026-08-09

  Reversine offers translational researchers a mechanistic lens for studying Aurora kinase signaling, mitotic checkpoint control, cancer cell proliferation inhibition, and apoptosis induction in cancer cells. This article connects checkpoint biology to practical assay design and a disciplined strategy for cancer research.

• Calpeptin: Calpain Inhibitor for Fibrosis Research

  2026-08-08

  Calpeptin is a nanomolar calpain inhibitor used to investigate calcium-dependent cysteine protease signaling. Product data report activity against human calpain 1 and reductions in fibrotic and inflammatory markers in fibroblast and mouse pulmonary fibrosis models.

• Mechanisms of Cell Death in Heart Disease

  2026-08-07

  This review reframes cardiac injury by showing that apoptosis and necrosis are distinct but interconnected outcomes of regulated signaling, rather than wholly separate or passive processes. Its pathway-based analysis offers practical guidance for interpreting cell-death phenotypes and for evaluating pharmacological interventions, while also defining limits on translating cardiovascular mechanisms to other disease models.

• LRRC8A-Caveolin-1 Axis Drives PDAC Growth via Cholesterol Re

  2026-08-07

  This study uncovers how a cholesterol-dependent LRRC8A-caveolin-1 complex sustains KRAS/EGFR signaling, ribosome biogenesis, and cell growth in pancreatic ductal adenocarcinoma. Elucidation of this axis highlights new mechanistic links between membrane dynamics and oncogenic progression, offering a potential therapeutic target in aggressive pancreatic cancer.

• FLAG tag Peptide: Strategic Leverage for Exosome Pathway Res

  2026-08-06

  This thought-leadership article explores the mechanistic and strategic value of the FLAG tag Peptide (DYKDDDDK) in advancing recombinant protein research, with a focus on translational applications in exosome biology. By integrating recent mechanistic insights into ESCRT-independent exosome pathways and best-in-class purification protocols, it provides actionable guidance for researchers seeking reproducibility and scalability in complex biological systems.

• BFH772 (VEGFR2 inhibitor): Protocols, QC, and Workflow Guida

  2026-08-06

  BFH772 is a potent, selective VEGFR2 inhibitor designed for researchers requiring precise inhibition of VEGFR2-driven angiogenesis, especially in tumor model studies. It is optimal for workflows emphasizing kinase selectivity and organic solvent compatibility, but is not suitable for protocols requiring water solubility or long-term solution storage.

15463 records 1/1031 page Next 12345 下5页 Last page